Literature DB >> 17602984

Usefulness of delayed enhancement magnetic resonance imaging to differentiate dilated phase of hypertrophic cardiomyopathy and dilated cardiomyopathy.

Fumitaka Matoh1, Hiroshi Satoh, Katsunori Shiraki, Takeji Saitoh, Tsuyoshi Urushida, Hideki Katoh, Yasuo Takehara, Harumi Sakahara, Hideharu Hayashi.   

Abstract

BACKGROUND: The dilated phase of hypertrophic cardiomyopathy (HCM) has a poor prognosis. For correct recognition of such patients, we compared the findings in cardiac delayed enhancement (DE)-magnetic resonance imaging (MRI) between HCM and dilated cardiomyopathy (DCM) patients. METHODS AND
RESULTS: Sixty-five patients (HCM 39, DCM 26) underwent gadolinium-DTPA-enhanced MRI. The HCM patients were divided into those with preserved (HCM-P, n = 30) and those with impaired systolic function (HCM-I, n = 9). DE-MRI demonstrated focal or diffuse DE at the left ventricular (LV) wall in 60% of HCM-P and 100% of HCM-I, but in only 12% of DCM. The DE distributed mainly septal to the anterior wall of LV, but the DE volume against whole LV muscle volume was much larger in HCM-I than in HCM-P and DCM (4.1 +/- 6.1% in HCM-P, 14.6 +/- 11.9% in HCM-I, and 0.8 +/- 2.4% in DCM, means +/- SD, P < .05). In HCM, there were weak but significant correlations between DE volume, and LV end-diastolic volume and LV end-systolic volume. In HCM-P, the percent of length shortening in the segments with DE was lower than that without DE.
CONCLUSIONS: The HCM patients had more DE than the DCM patients, and DE volume correlated to lower global and local LV function. DE-MRI may be useful to evaluate myocardial damage in HCM patients, and to differentiate the dilated phase of HCM from DCM.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17602984     DOI: 10.1016/j.cardfail.2007.02.001

Source DB:  PubMed          Journal:  J Card Fail        ISSN: 1071-9164            Impact factor:   5.712


  14 in total

Review 1.  The role of cardiac magnetic resonance imaging in the assessment of non-ischemic cardiomyopathy.

Authors:  Mouaz H Al-Mallah; Mohammad Naseem Shareef
Journal:  Heart Fail Rev       Date:  2011-07       Impact factor: 4.214

2.  3.0 T magnetic resonance myocardial perfusion imaging for semi-quantitative evaluation of coronary microvascular dysfunction in hypertrophic cardiomyopathy.

Authors:  Liang Yin; Hai-Yan Xu; Sui-Sheng Zheng; Ying Zhu; Jiang-Xi Xiao; Wei Zhou; Si-Si Yu; Liang-Geng Gong
Journal:  Int J Cardiovasc Imaging       Date:  2017-06-13       Impact factor: 2.357

Review 3.  Identifying the etiology: a systematic approach using delayed-enhancement cardiovascular magnetic resonance.

Authors:  Annamalai Senthilkumar; Maulik D Majmudar; Chetan Shenoy; Han W Kim; Raymond J Kim
Journal:  Heart Fail Clin       Date:  2009-07       Impact factor: 3.179

Review 4.  Distribution of late gadolinium enhancement in various types of cardiomyopathies: Significance in differential diagnosis, clinical features and prognosis.

Authors:  Hiroshi Satoh; Makoto Sano; Kenichiro Suwa; Takeji Saitoh; Mamoru Nobuhara; Masao Saotome; Tsuyoshi Urushida; Hideki Katoh; Hideharu Hayashi
Journal:  World J Cardiol       Date:  2014-07-26

5.  Extent of late gadolinium enhancement at right ventricular insertion points in patients with hypertrophic cardiomyopathy: relation with diastolic dysfunction.

Authors:  Yinsu Zhu; Eun-Ah Park; Whal Lee; Hyung-Kwan Kim; Ajung Chu; Jin Wook Chung; Jae Hyung Park
Journal:  Eur Radiol       Date:  2015-01-18       Impact factor: 5.315

6.  Ischemic and non-ischemic patterns of late gadolinium enhancement in heart failure with reduced ejection fraction.

Authors:  Patrycja S Matusik; Amira Bryll; Paweł T Matusik; Tadeusz J Popiela
Journal:  Cardiol J       Date:  2020-02-10       Impact factor: 2.737

7.  CMR assessment and clinical outcomes of hypertrophic cardiomyopathy with or without ventricular remodeling in the end-stage phase.

Authors:  Sainan Cheng; Yeon Hyeon Choe; Hideki Ota; Chen Cui; Gang Yin; Minjie Lu; Lu Li; Xiuyu Chen; Sanjay K Prasad; Shihua Zhao
Journal:  Int J Cardiovasc Imaging       Date:  2017-10-25       Impact factor: 2.357

8.  Role of Cardiac MRI in the Assessment of Cardiomyopathy.

Authors:  Róisín B Morgan; Raymond Kwong
Journal:  Curr Treat Options Cardiovasc Med       Date:  2015-11

9.  Rest perfusion abnormalities in hypertrophic cardiomyopathy: correlation with myocardial fibrosis and risk factors for sudden cardiac death.

Authors:  A Chiribiri; S Leuzzi; M R Conte; S Bongioanni; K Bratis; L Olivotti; C De Rosa; E Lardone; P Di Donna; A D M Villa; F Cesarani; E Nagel; F Gaita; R Bonamini
Journal:  Clin Radiol       Date:  2015-02-07       Impact factor: 2.350

10.  Functional, morphological and electrocardiographical abnormalities in patients with apical hypertrophic cardiomyopathy and apical aneurysm: correlation with cardiac MR.

Authors:  Kenichiro Suwa; Hiroshi Satoh; Makoto Sano; Mamoru Nobuhara; Takeji Saitoh; Masao Saotome; Tsuyoshi Urushida; Hideki Katoh; Kei Tawarahara; Hayato Ohtani; Yasushi Wakabayashi; Hiroyuki Takase; Hajime Terada; Yasuo Takehara; Harumi Sakahara; Hideharu Hayashi
Journal:  Open Heart       Date:  2014-08-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.